Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Exclusion Criteria

• •Females who are pregnant or breastfeeding
• •Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
• •Coinfection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV)
• •Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is \< 50 ng/mL no imaging study is needed; however, if the screening AFP is \> 50 ng/mL an imaging study is required)
• •Any history of, or current evidence of, clinical hepatic decompensation
• •Abnormal hematological and biochemical parameters
• •Chronic liver disease of non-HBV etiology (e.g., hemochromatosis, alpha-1 antitrypsin deficiency, cholangitis)
• •Received solid organ or bone marrow transplant
• •Currently receiving therapy with immunomodulators (eg, corticosteroids), or immunosuppressants
• •Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the Investigator
• •Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance.